{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001737287","name":"Allogene Therapeutics, Inc.","summary":"Allogene Therapeutics is a clinical-stage immuno-oncology company developing off-the-shelf allogeneic CAR T cell therapies derived from healthy donors for use in any patient. Core programs include cema-cel (CD19-targeting) for large B-cell lymphoma, ALLO-316 (CD70-targeting) for renal cell carcinoma, and ALLO-329 (CD19/CD70-targeting) for autoimmune diseases including SLE. The company uses TALEN and CRISPR gene-editing technologies and operates its own cGMP manufacturing facility, Cell Forge 1, in Newark, California.","people":[],"products":[{"name":"Cemacabtagene ansegedleucel (cema-cel / ALLO-501A)","type":"platform","description":"Allogeneic CD19-targeting CAR T cell product candidate in pivotal Phase 2 (ALPHA3) trial for first-line large B-cell lymphoma consolidation."},{"name":"ALLO-316","type":"platform","description":"Allogeneic CD70-targeting CAR T cell product candidate in Phase 1 (TRAVERSE) trial for advanced or metastatic renal cell carcinoma."},{"name":"ALLO-329","type":"platform","description":"Allogeneic CAR T cell product candidate targeting both CD19 and CD70, in Phase 1 (RESOLUTION) trial for autoimmune diseases including SLE, IIM, and SSc."}],"partnerships":[{"partner_name":"Les Laboratoires Servier SAS / Institut de Recherches Internationales Servier SAS","partnership_type":"licensing","description":"Exclusive License and Collaboration Agreement granting rights to develop and commercialize cema-cel and additional product candidates, including access to Cellectis TALEN gene-editing technology.","start_date":null},{"partner_name":"Cellectis, S.A.","partnership_type":"licensing","description":"Exclusive worldwide oncology license to use TALEN gene-editing technology for allogeneic T cell product candidates directed against 15 cancer antigens including CD70.","start_date":null},{"partner_name":"Arbor Biotechnologies","partnership_type":"licensing","description":"Non-exclusive license for CRISPR-based gene-editing technology for allogeneic T cell product candidates in autoimmune diseases targeting CD19 and CD70.","start_date":null},{"partner_name":"Pfizer Inc.","partnership_type":"acquisition","description":"Acquired strategic license agreements, collaboration agreements, and intellectual property related to allogeneic CAR T cell therapy in April 2018.","start_date":null},{"partner_name":"Foresight Diagnostics (acquired by Natera)","partnership_type":"development","description":"Leveraging Foresight Diagnostics investigational assay to identify MRD-positive LBCL patients in the ALPHA3 trial.","start_date":null}],"affiliations":[],"origin":{"leaf":"82d7d832b09b7f9f570fa1e989b427d83e1b65da1f00d193027aa056c0c21020","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"0dd505e1ab33ffcde1d772c0a0b594224701a82572edb44c545e7672b41027ba","parent":"3b07c425d47f34f2d9d7d9a9273497b66da4ecbfc63f32660cec1fe5b63351f3","source":"0001628280-26-017242","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":144,"hourly_limit":500,"remaining":356,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}